The prevalence of fluoroquinolone resistance mechanisms in colonizing escherichia coli isolates recovered from hospitalized patients

Clinical Infectious Diseases

Volumn 51, Issue 3, 2010, Pages 280-285

  Lautenbach, Ebbing ^a,c,d,e   Metlay, Joshua P ^b,c,d,e   Mao, Xiangqun ^c   Han, Xiaoyan ^d   Fishman, Neil O ^a,e   Bilker, Warren B ^c,d,e   Tolomeo, Pam ^d   Wheeler, Mary ^d   Nachamkin, Irving ^c,e  

^a Division of Infectious Diseases   (United States)

^b Div of General Internal Medicine   (United States)

^c Department of Biostatistics and Epidemiology ^*  (United States)

^d Center for Clinical Epidemiology and Biostatistics   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; NALIDIXIC ACID; ORGANIC SOLVENT; PROTEIN PARC; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ESCHERICHIA COLI PROTEIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; GASTROINTESTINAL TRACT; GENE MUTATION; HOSPITAL PATIENT; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SAMPLING; AMINO ACID SUBSTITUTION; BACTERIUM IDENTIFICATION; CHEMISTRY; CLASSIFICATION; DNA FINGERPRINTING; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; FECES; GENETICS; HETEROZYGOTE; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MISSENSE MUTATION;

AGED; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CARRIER STATE; DNA FINGERPRINTING; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FECES; FEMALE; FLUOROQUINOLONES; HOSPITALS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; PREVALENCE;

EID: 77954704109     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653931     Document Type: Article

References (35)

1. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118:259-268.
2. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000; 30:243-254.
3. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, (1989-2000): differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38:655-662.
4. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 2003; 289:885-888.
5. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: role of inadequate empiric antimicrobial therapy. Clin Infect Dis 2005; 41:923-929.
6. Bettelheim KA. The genus Escherichia. New York: Springer-Verlag, 1991.
7. Arbeit RD, Arthur M, Dunn R, Kim C, Selander RK, Goldstein R. Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J Infect Dis 1990; 161:230-235.
8. Brumfitt W. Progress in understanding urinary infections. J Antimicrob Chemother 1991; 27:9-22.
9. Oethinger M, Jellen-Ritter AS, Conrad S, Marre R, Kern WV. Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 1998; 26:379-384.
10. Everett MJ, Jin YF, Ricci V, Piddock LJV. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996; 40:2380-2386.
11. McDonald LC, Chen FJ, Lo HJ, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001; 45:3084-3091.
12. Oethinger M, Kern WV, Goldman JD, Levy SB. Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J Antimicrob Chemother 1998; 41:111-114.
13. Ozeki S, Deguchi T, Yasuda M, et al. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections. J Clin Microbiol 1997; 35:2315-2319.
14. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-3232.
15. Park YH, Yoo JH, Huh DH, Cho YK, Choi JH, Shin WS. Molecular analysis of fluoroquinolone resistance in Escherichia coli on the aspect of gyrase and multiple antibiotic resistance (mar) genes. Yonsei Med J 1998; 39:534-540.
16. Lautenbach E, Fishman NO, Metlay JP, et al. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006; 194:79-85.
17. Lautenbach E, Harris AD, Perencevich EN, Nachamkin I, Tolomeo P, Metlay JP. Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract. Antimicrob Agents Chemother 2005; 49:798-800.
18. Ling TK, Tam PC, Liu ZK, Cheng AF. Evaluation of VITEK 2 rapid identification and susceptibility testing system against gram-negative clinical isolates. J Clin Microbiol 2001; 39:2964-2966.
19. Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991; 29:533-538.
20. Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from china: role of acrR mutations. Antimicrob Agents Chemother 2001; 45:1515-1521.
21. Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic- resistance (Mar) mutants. J Bacteriol 1996; 178:306-308.
22. Oethinger M, Kern WV, Jellen-Ritter AS, McMurry LM, Levy SB. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the acrAB efflux pump. Antimicrob Agents Chemother 2000; 44:10-13.
23. White DG, Goldman JD, Demple B, Levy SB. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J Bacteriol 1997; 179:6122-6126.
24. Gautom RK. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 1997; 35:2977-2980.
25. Goering RV, Tenover FC. Epidemiological interpretation of chromosomal macro-restriction fragment patterns analyzed by pulsed-field gel electrophoresis. J Clin Microbiol 1997; 35:2432-2433.
26. Lautenbach E. Antimicrobial resistance in gram-negative pathogens: crafting the tools necessary to navigate the long ascent out of the abyss. J Infect Dis 2009; 200:838-840.
27. Johnson JK, Smith G, Lee MS, et al. The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis 2009; 200:900-905.
28. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold, 1982.
29. Ruiz J, Gomez J, Navia MM, et al. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis 2002; 42:257-261.
30. Tavio MM, Vila J, Ruiz J, Ruiz J, Martin-Sanchez AM, Jimenez de Anta MT. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother 1999; 44:735-742.
31. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41(suppl 2):S120-S126.
32. Lehn N, Stower-Hoffman J, Kott T, et al. Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol 1996; 34:597-602.
33. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother 2000; 44:2233-2241.
34. Lautenbach E, Bilker WB, Tolomeo P, Maslow JN. Impact of diversity of colonizing strains on strategies for sampling Escherichia coli from fecal specimens. J Clin Microbiol 2008; 46:3094-3096.
35. Lautenbach E, Tolomeo P, Black N, Maslow JN. Risk factors for fecal colonization with multiple distinct strains of Escherichia coli among long-term care facility residents. Infect Control Hosp Epidemiol 2009; 30:491-493.